Literature DB >> 6152176

Failure of 'therapeutic' doses of beta-adrenoceptor antagonists to alter the disposition of tolbutamide and lignocaine.

J O Miners, L M Wing, K J Lillywhite, K J Smith.   

Abstract

The effects of separate 1 week pre-treatments with each of the beta-adrenoceptor antagonists, propranolol (80 mg every 12 h), metoprolol (100 mg every 12 h) and atenolol (50 mg once daily), on the disposition of a single i.v. dose of tolbutamide were studied in six healthy volunteers. In addition, the effects of a 1 week pre-treatment with metoprolol (100 mg every 12 h) and atenolol (50 mg once daily) on the disposition of orally and i.v. administered lignocaine were determined in seven healthy subjects. Tolbutamide clearance, half-life, volume of distribution and plasma protein binding were not altered by the beta-adrenoceptor blocker pre-treatments. Similarly, neither metoprolol nor atenolol had a significant effect on the systemic clearance, apparent oral clearance or other dispositional parameters of lignocaine. 'Therapeutic' plasma concentrations of the beta-adrenoceptor blockers were confirmed on each study day. It is concluded that the inhibition of oxidative drug metabolism previously reported for lipophilic beta-adrenoceptor blockers may be selective for different forms of cytochrome P450 and possible concentration-dependent.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6152176      PMCID: PMC1463673          DOI: 10.1111/j.1365-2125.1984.tb02555.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  23 in total

1.  Clinical pharmacokinetics of beta-adrenoreceptors blockers.

Authors:  G Johnsson; C G Regårdh
Journal:  Drugs       Date:  1976       Impact factor: 9.546

2.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

3.  Clinical pharmacokinetics of atenolol.

Authors:  J McAinsh
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

4.  The reduction of lidocaine clearance by dl-propranolol: an example of hemodynamic drug interaction.

Authors:  R A Branch; D G Shand; G R Wilkinson; A S Nies
Journal:  J Pharmacol Exp Ther       Date:  1973-02       Impact factor: 4.030

5.  The tissue distribution, metabolism and excretion of lidocaine in rats, guinea pigs, dogs and man.

Authors:  J B Keenaghan; R N Boyes
Journal:  J Pharmacol Exp Ther       Date:  1972-02       Impact factor: 4.030

6.  The metabolic fate of tolbutamide in man and in the rat.

Authors:  R C Thomas; G J Ikeda
Journal:  J Med Chem       Date:  1966-07       Impact factor: 7.446

7.  The use of drug concentration measurements in studies of the therapeutic response to propranolol.

Authors:  C Chidsey; M Pine; L Favrot; S Smith; G Leonetti; P Morselli; A Zanchetti
Journal:  Postgrad Med J       Date:  1976       Impact factor: 2.401

8.  Lidocaine disposition--sex differences and effects of cimetidine.

Authors:  L M Wing; J O Miners; D J Birkett; T Foenander; K Lillywhite; S Wanwimolruk
Journal:  Clin Pharmacol Ther       Date:  1984-05       Impact factor: 6.875

9.  Lidocaine elimination: effects of metoprolol and of propranolol.

Authors:  K A Conrad; J M Byers; P R Finley; L Burnham
Journal:  Clin Pharmacol Ther       Date:  1983-02       Impact factor: 6.875

10.  Impairment of antipyrine clearance in humans by propranolol.

Authors:  D J Greenblatt; K Franke; D H Huffman
Journal:  Circulation       Date:  1978-06       Impact factor: 29.690

View more
  14 in total

Review 1.  beta-blockers. Drug interactions of clinical significance.

Authors:  I Blaufarb; T M Pfeifer; W H Frishman
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

Review 2.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

3.  The impairment of lignocaine clearance by propranolol--major contribution from enzyme inhibition.

Authors:  N D Bax; G T Tucker; M S Lennard; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

4.  Selectivity and dose-dependency of the inhibitory effect of propranolol on theophylline metabolism in man.

Authors:  J O Miners; L M Wing; K J Lillywhite; R A Robson
Journal:  Br J Clin Pharmacol       Date:  1985-09       Impact factor: 4.335

5.  Propranolol does not alter flutoprazepam kinetics and metabolism in the rat.

Authors:  I Conti; S Sarati; S Caccia
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

6.  The effect of propranolol on paracetamol metabolism in man.

Authors:  O Z Baraka; C A Truman; J M Ford; C J Roberts
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

7.  Lack of effect of atenolol and nadolol on the metabolism of theophylline.

Authors:  C M Corsi; A N Nafziger; J A Pieper; J S Bertino
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

Review 8.  The pharmacokinetics of lignocaine and beta-adrenoceptor antagonists in patients with acute myocardial infarction.

Authors:  S Nattel; G Gagne; M Pineau
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

9.  Co-regulation of phenytoin and tolbutamide metabolism in humans.

Authors:  W Tassaneeyakul; M E Veronese; D J Birkett; C J Doecke; M E McManus; L N Sansom; J O Miners
Journal:  Br J Clin Pharmacol       Date:  1992-12       Impact factor: 4.335

10.  Novel in vitro dynamic metabolic system for predicting the human pharmacokinetics of tolbutamide.

Authors:  Cai-Fu Xue; Zhe Zhang; Yan Jin; Bin Zhu; Jun-Fen Xing; Guo Ma; Xiao-Qiang Xiang; Wei-Min Cai
Journal:  Acta Pharmacol Sin       Date:  2018-04-12       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.